Search research articles
Contact Us
Filters
Showing results (71-80 of 198) with videos related to
Page
of 20
Sort By:
Rheumatology and Therapy
|
August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2003
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium
Philip N Sambrook, Mark Kotowicz, Peter Nash, et al.
Journal of Comparative Effectiveness Research
|
February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
Vibeke Strand, Iain McInnes, Philip Mease, et al.
Annals of the Rheumatic Diseases
|
October 7, 2021
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Kevin L Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Clinical Therapeutics
|
August 4, 2010
Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study
Lachlan Standfield, Sarah Norris, Charles Harvey, et al.
Advances in Therapy
|
April 19, 2017
Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study
Marc Egeth, Jennifer Soosaar, Peter Nash, et al.
Rheumatology (Oxford, England)
|
July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Mark C Genovese, Benard Combe, Joel M Kremer, et al.
Clinical and Experimental Rheumatology
|
December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
Arthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
Rheumatology and Therapy
|
March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Richard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy
|
March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Page
of 20
Search research articles
Search
Showing results (71-80 of 198) with videos related to
Sort By:
Page
of 20
Rheumatology and Therapy
|
August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
May 8, 2003
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium
Philip N Sambrook, Mark Kotowicz, Peter Nash, et al.
Journal of Comparative Effectiveness Research
|
February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
Vibeke Strand, Iain McInnes, Philip Mease, et al.
Annals of the Rheumatic Diseases
|
October 7, 2021
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Kevin L Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Clinical Therapeutics
|
August 4, 2010
Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study
Lachlan Standfield, Sarah Norris, Charles Harvey, et al.
Advances in Therapy
|
April 19, 2017
Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study
Marc Egeth, Jennifer Soosaar, Peter Nash, et al.
Rheumatology (Oxford, England)
|
July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Mark C Genovese, Benard Combe, Joel M Kremer, et al.
Clinical and Experimental Rheumatology
|
December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
Arthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
Rheumatology and Therapy
|
March 15, 2024
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Richard B Warren, Iain B McInnes, Peter Nash, et al.
Rheumatology and Therapy
|
March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Philip J Mease, Richard B Warren, Peter Nash, et al.
Page
of 20